We restore endothelial cell function
About Pantherna
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium.
Latest News
PRESS RELEASE
11 January, 2022
Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs
Hennigsdorf, January 11, 2022 – Pantherna Therapeutics today announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).
Our Team
Our Locations
Headquarters
Pantherna Therapeutics GmbH
Innovationsforum Hennigsdorf
Neuendorfstrasse 20b
D-16761 Hennigsdorf
Germany
R&D Site
Pantherna Therapeutics GmbH
Bayer AG CoLaborator Berlin
Müllerstraße 178
D-13353 Berlin
Germany
